GALNT6 and ovarian carcinoma: Our observations were further confirmed in silico based on the analysis of the GALNT6 expression profiles from publicly available data [13], and upon using the Kaplan–Meier plotter human ovarian cancer data sets [25] for high-grade serous EOC patients, with a follow-up threshold of 60 months (accessible via http://www.kmplot.com/ovar web portal; data not shown).